The effects of blood pressure on post stroke cognitive impairment: BP and PSCI

Yue Wang MD1,2 | Shiping Li MD, PhD1 | Yuesong Pan PhD1 | Mengxing Wang BD1 | Xiaoling Liao MD, PhD1,2 | Jiong Shi MD, PhD1,2 | Yongjun Wang MD1,2

1 National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China
2 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China

Correspondence
Yongjun Wang and Jiong Shi, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing 100070, People’s Republic of China. Email: yongjunwang@ncrcnd.org.cn and jiongshi@ncrcnd.org.cn

Abstract
Cognitive function following acute ischemic stroke (AIS) is critical to prognosis and quality of life. Hypertension is a risk factor for stroke and is associated with post stroke cognitive impairment (PSCI). However, the optimal blood pressure parameters after AIS is unknown. This is a sub-study of the Impairment of Cognition and Sleep after acute ischemic stroke or transient ischemic attack in Chinese patients (ICONS) study conducted between August 2015 and March 2018. Cognition was assessed at two-week (2w), three-month (3m), and twelve-month (12m) by Montreal Cognitive Assessment (MoCA). A total of 682 participants who met the inclusion criteria were enrolled. The primary outcome was cognitive changes after 3 and 12 months post stroke. Among 682 participants, the mean age was 59.35 ± 10.40 years and 72.29% were men. PSCI patients with high systolic blood pressure (SBP ≥ 140 mm Hg) at 3 m not only had worse cognition as evidenced by MoCA scores at 3m but also predicted worse scores at 12 m. When participants were stratified into cognitively stable/improved (MoCA score ≥ 0, 2w vs. 12m) and cognitively impaired (MoCA score ≤ -2, 2w vs. 12 m), those with high SBP were more likely to be cognitively impaired (OR 2.17, 95%CI 1.12–4.21, p < .05) and less likely to be cognitively stable/improved (OR 0.66, 95%CI 0.44–0.99, p < .05). SBP more than 140 mm Hg is associated with worse cognitive performance after ischemic stroke. Patients with SBP lower than 140 mm Hg have better cognitive outcome at 3-month and 1 year after stroke.

KEYWORDS
hypertension, post stroke cognitive impairment, stroke

1 INTRODUCTION

Post stroke cognitive impairment (PSCI) is a common cause of morbidity and disability in cerebrovascular disease.1-2 Hypertension is a risk factor for both stroke and dementia.3-5 Effective treatment of hypertension and cardiac disease help cognitive performance in long the term.5,6 However, data from clinical trials designed to demonstrate the benefits of tight blood pressure control on cognition in stroke patients have been inconclusive.7-9 Intensive systolic blood pressure (SBP) control (less than 120 mm Hg) did not significantly reduce dementia risk but did have a measurable impact on mild cognitive impairment.10 Furthermore, permissive hypertension in the immediate post stroke phase is a recognized option in stroke guidelines regarding early penumbra preservation.11 Whether this is more or less relevant to cognitively

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC

J Clin Hypertens. 2021;23:2100–2105.
compromised stroke patients with less cerebral plasticity requires further investigation. In this pre-specified sub-study of the Impairment of Cognition and Sleep after acute ischemic stroke (ICONS) study, we examined what blood pressure parameters are beneficial to these at risk patients who had cognitive deficits after stroke.

2 METHODS

2.1 Study design and participants

We used the database of the ICONS study which was conducted at 40 clinical centers in China from August 2015 to April 2018. In this sub-study, patients were selected who were within 7 days of confirmed diagnosis of acute ischemic stroke (AIS) on MRI. They completed face to face visits with Montreal Cognitive Assessment (MoCA) tests and blood pressure assessments at 2-week (2w), 3-month (3 m), and 12-month (12 m) after AIS. The blood pressure was measured with the participant in a seated position after 5 min rest. The position of the automated sphygmomanometer (OMRON Model HEM-7071, Omron Co. Ltd.) was at the heart level. Measurements were taken two times consecutively on the non-dominant arm, with 1-min interval. Blood pressure was recorded as the average of the two measurements. Medications and other medical information were recorded. The trial was approved by the ethics committee of each medical institution. Written informed consent was obtained from all participants or their legal guardians.

According to 2020 International Society of Hypertension Global Hypertension Practice Guideline, patients were divided into three groups according to their SBP and DBP ranges at 3 and 12 m visits: SBP < 130 mm Hg and/or DBP < 85 mm Hg (normal BP), SBP 130–140 mm Hg and/or DBP 85–89 mm Hg (normal-high BP), SBP ≥140 mm Hg and/or DBP ≥90 mm Hg (high BP).

2.2 Outcomes

The safety outcomes in this analysis were similar to those of the ICONS study. The primary efficacy outcome was cognitive decline or improvement at 3 m and 12 m visits compared to the 2w visit, as well as the MoCA scores at 3 m and 12 m visits. MoCA is widely used and has been validated as efficacious in post stroke assessment of cognition due to its sensitivity and specificity in determining mild cognitive impairment (MCI). Cognitive decline is defined as a reduction in MoCA score of two or more points (one standard deviation, SD), and cognitive improvement as an increase of two or more points.

2.3 Statistical analysis

We presented continuous variables as mean ± SD or median with interquartile and categorical variables as percentages. T test or Wilcoxon rank sum test was used for continuous variables and chi-square test for categorical variables. We compared the factors in these cases with SBP or DBP ranges at 3 m and 12 m visits. All significant covariates (p < .05) in the univariable analyses were adjusted in the corresponding multivariable model (Model 3). Demographic characters were analyzed by logistic regression of different models (Model 1: age, sex, and years of education; Model 2: age, sex, years of education and Modified Rankin Scale (MRS): Model 3: age, sex, years of education, MRS, recurrence of stroke and the classification of Trial of Org 10172 in Acute Stroke Treatment (TOAST). Participants with recurrent AIS were removed in this regression analysis as these obviously distorted the figures. Unadjusted and adjusted odds ratios (ORs) and their 95% confidence intervals (CI) were calculated separately. The α level of significance was determined as p < .05, two-sided. All analyses were performed with SAS 9.4 software.

3 RESULTS

A total of 682 participants were enrolled in this study. The demographic characters of patients in three groups based on their SBP at 3 m were shown in Table 1. The number of participants in each group were similar. Participants in the high SBP group (≥140 mm Hg) were older, more female, more likely to have recurrent AIS at 3 m. High SBP was associated with worse MoCA scores. Noteworthy, patients with high SBP had worse MoCA scores not only at 3 m but also at 12 m (p < .0001), suggesting high SBP at 3 m had a poor prognosis for cognition at 12 m. To validate the relationship between high SBP and cognition at 12 m, we divided participants into three SBP groups at 12 m (Table 2). Participants in the high SBP group (≥140 mm Hg) consistently had worse MoCA scores (p < .0001). They were also older and had worse scores of mRS. In terms of DBP, high DBP at 3 m was associated with high BMI and high incidence of bleeding after admission, but not with cognitive performance (Table S1). DBP at 12 m had no correlation with stroke or cognitive function (Table S2).

To further validate the relationship between different SBP and cognition, we divided participants into the cognitively stable/improved and cognitive impaired groups based on their MoCA scores at 12 m compared to 2w. The cognitively stable/improved group was younger, less likely to have a history of hypertension. The cognitively impaired group was more likely to have previous strokes and an undetermined cause of TOAST type, recurrent AIS and worse mRS scores (Table 3). Recurrent AIS obviously influence the results, after removing them, 632 participants were analyzed in logistic regression of different models, when age, sex, and education were taken into consideration, participants with high SBP were more likely to be cognitively impaired (Table 4, Model 1: OR 2.02, 95%CI 1.06–3.84, p = .0322). The strength of the association between high SBP and cognitive impairment was robust when taken in all other factors in addition to age, sex, and education (Table 4, model 3: OR 0.66 (95%CI 0.44–0.99), p = .0451; OR 2.17 (95%CI 1.12–4.21), p = .0226, respectively).

4 DISCUSSION

In this study, we have demonstrated the benefits of hypertension control on cognitive performance, when controlled for all other parame-
Hypertension plays a critical role in both salvaging and risk-
ing ideal post-stroke blood pressure parameters especially in vulnerable patients with cognitive deficits after stroke.8,9 There is no correlation between DBP and cognitive performance. SBP is considered a stronger predictor of blood pressure related outcomes than DBP.20,21 A meta-analysis has demonstrated that SBP has a linear effect on cognitive decline, and lower SBP levels are associated with slower cognitive decline of later life.22

A smaller study recruited patients with first-ever stroke who achieved SBP in the categories ≤125 mm Hg, ≤140 mm Hg, and ≤160 mm Hg. SBP reduction of ≥10 mm Hg, and DBP reduction of ≥5 mm Hg. It showed a potential beneficial effect of blood pressure control on cognitive function (\( \rho = .070–1.00 \)), suggesting longer follow-up and/or larger sample size were needed to demonstrate significance.23 A sub-analysis of the Secondary Prevention of Small Subcortical Strokes Study (SPS3) trial assessed the effects of blood pressure control and single/dual antiplatelet treatment on cognition. It recruited patients with recent (within 6 months) symptomatic lacu-
nar infarcts and tested their blood pressure and cognition annually. It didn’t show significant changes in cognitive function over time between assigned antiplatelet groups (p = .858) or between assigned blood pressure target groups (SBP 130–149 mm Hg vs. < 130 mm Hg, p = .520), suggesting targeted stratification of SBP groups and earlier intervention are critical.

Stroke scales are designed to rapidly localize the presence or risk of stroke to large and small vessel territories. Cognitive tests are designed to measure function at targeted domains of the brain. Cognitive measures such as MoCA are likely to capture more subtle losses of function than stroke scales and are designed to show progressive performance change rather than acute risk. While stroke studies have focused on the presence of recurrent stroke, a recent study indicated that cognitive measures correlated more with blood pressure and cardiac parameters than recurrent TIA or stroke events. Hypertension at 3 m is associated with higher recurrence rate of AIS within 3 m and worse long term mRS scores at 12 m. Recurrent AIS can impact negatively on cognition. However, after excluding the effects of recurrent AIS, SBP still has significant impact on cognitive performance (Table 4, model 3).

There are several limitations of the study. First, this is a prospective observational study. Age, sex, and education levels were not tightly controlled for study groups. Since all of them can affect cognition, we used logistic regression analysis (model 1) to discount their effects. Second, blood pressure is likely to fluctuate in the period of 1 year. It has been shown that the fluctuations in blood pressure have predictive values in patients with stroke, a potential risk factor for cognitive decline in dementia. We tried to limit this fluctuation by multiple analysis at 3 m and 12 m. The results from these two time points are consistent. Third, stroke-like symptoms could mimic stroke and compromise the accuracy of diagnosis of PSCI. We required MRI imaging evidence of stroke to exclude stroke mimics for this study. Future studies should attempt to correlate MRI stroke region with cognitive performance and potentially localize at risk subtypes.

In conclusions, this study has shown that hypertension (SBP>140 mm Hg), as an independent risk factor, has detrimental effects on cognitive function after initial AIS. Navigating appropriate blood pressure parameters in PSCI patients with various risk factors for stroke and dementia is difficult. However, determining appropriate parameters for this at risk population may provide effective protection against further decline.

ACKNOWLEDGMENTS
We would like to thank the centers, patients and their caregivers participated in the Impairment of CogniTON and Sleep after acute ischemic stroke or transient ischemic attack in Chinese patients study. This study is supported by Beijing Municipal Science & Technology Commission (Grant No. D171100003017002 and Z181100001518005), National Key R&D Program of China (Grant No.

| TABLE 2 | Demographic, clinical characteristics and outcomes of patients with different SBP ranges at 12 months |
|-----------------------------------------------|-----------------------------------------------|
| | SBP < 130 mm Hg | 130≤SBP < 140 mm Hg | SBP≥140 mm Hg |
| | N = 244, n (%) | N = 226, n (%) | N = 212, n (%) |
| Average age (years, mean ± SD) * | 57.77±10.16 | 59.20±10.48 | 61.32±10.30 |
| Sex male (%) | 65 (26.64) | 54 (23.89) | 70 (33.02) |
| Years of education (years, mean ± SD) * | 9.01±2.26 | 8.92±2.28 | 8.48±2.25 |
| Current smokers | 97 (39.75) | 93 (41.15) | 68 (32.08) |
| Current drinkers | 43 (17.62) | 54 (23.89) | 46 (21.70) |
| Heavy drinkers (> 60 g/d) | 39 (15.98) | 45 (19.91) | 41 (19.34) |
| BMI (mean±SD) | 24.90±3.20 | 25.23±3.10 | 25.21±3.15 |
| History of coronary heart disease | 21 (8.61) | 25 (11.06) | 14 (6.60) |
| History of Atrial fibrillation | 9 (3.69) | 9 (3.98) | 7 (3.30) |
| TOAST | | | |
| Large artery atherosclerosis | 56 (22.95) | 45 (19.91) | 53 (25.00) |
| Cardiogenic embolism | 12 (4.92) | 11 (4.87) | 10 (4.72) |
| Small artery occlusion | 83 (34.02) | 66 (29.20) | 63 (29.72) |
| Another determined cause | 3 (1.23) | 1 (0.44) | 1 (0.47) |
| An undetermined cause | 90 (36.89) | 103 (45.58) | 85 (40.09) |
| GAD-7 at 12 m (mean±SD) | 1.51±3.04 | 1.42±2.55 | 1.81±3.62 |
| MOCA at 12 m (mean±SD) * | 24.95±4.77 | 24.08±4.86 | 22.77±4.78 |
| mRS at 12 m (mean±SD) | 0.65±0.80 | 0.72±0.81 | 0.85±0.85 |
| Recurrence of AIS at 12 m | 17 (6.97) | 12 (5.31) | 21 (9.91) |
| Recurrence of haemorrhagic stroke at 12 m | 0 | 2 (0.88) | 1 (0.47) |

Abbreviations: BMI, body mass index; GAD-7, General Anxiety Disorder-7; mRS, modified Ranking Scales; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; SD, standard deviation. *P<0.05.
### TABLE 3  Demographic, clinical characteristics and vascular risk factors of patients with different cognitive outcomes

|                                      | Cognitively stable/improved N = 607, n (%) | Cognitively impaired N = 75, n (%) | P value |
|-------------------------------------|-------------------------------------------|-----------------------------------|---------|
| Average age (years, mean± SD)       | 58.93±10.33                               | 62.77±10.41                      | .0050   |
| Sex male                            | 444 (73.15)                                | 49 (65.33)                       | .1538   |
| Years of education (years, mean± SD)| 8.80±2.25                                  | 8.96±2.49                        | .6161   |
| Current smokers                     | 232 (38.22)                                | 26 (34.67)                       | .5493   |
| Current drinkers                    | 124 (20.43)                                | 19 (25.33)                       | .3249   |
| Heavy drinkers (> 60 g/d)           | 108 (17.79)                                | 17 (22.67)                       | .3033   |
| BMI (mean±SD)                       | 25.16±3.18                                 | 24.62±2.87                       | .2432   |
| History of hypertension             | 342 (56.74)                                | 52 (69.33)                       | .0316   |
| History of diabetes                 | 116 (19.11)                                | 15 (20.00)                       | .8536   |
| History of coronary heart disease   | 53 (8.73)                                  | 7 (9.33)                         | .8622   |
| History of atrial fibrillation      | 22 (3.62)                                  | 3 (4.00)                         | .8703   |
| TOAST*                              |                                           |                                   | .0046   |

- Large artery atherosclerosis: 135 (22.24) vs. 19 (25.33), OR = 0.68 (0.46–1.02), p = .0628
- Cardiogenic embolism: 29 (4.78) vs. 4 (5.33)
- Small artery occlusion: 186 (30.64) vs. 26 (34.67)
- Another determined cause: 2 (0.33) vs. 3 (4.00)
- An undetermined cause: 255 (42.01) vs. 23 (30.67)
- GAD-7 at 2 weeks (mean±SD): 2.289±3.52 vs. 2.587±4.26, OR = 0.7228
- GAD-7 at 12 months (mean±SD): 1.48±2.84 vs. 2.38±4.57, OR = 0.3482
- NIHSS (admission, mean±SD): 3.65±3.14 vs. 3.08±2.43, OR = 0.1804
- NIHSS (discharge, mean±SD): 1.78±1.96 vs. 1.84±2.01, OR = 0.8106
- mRS (admission, mean±SD): 0.21±0.60 vs. 0.27±0.66, OR = 0.2833
- mRS (discharge, mean±SD): 1.09±1.00 vs. 1.04±0.88, OR = 0.9462
- mRS at 12 m (mean±SD): 0.70±0.78 vs. 1.03±1.07, OR = 0.0108
- Recurrence of ischemic stroke*: 37 (6.10) vs. 13 (17.33), OR = 0.0004
- Bleeding after admission: 10 (1.65) vs. 0, OR = 0.2628
- Recurrence of haemorrhagic stroke at 3 m: 1 (0.16) vs. 0, OR = 0.7250
- Recurrence of haemorrhagic stroke at 12 m: 2 (0.33) vs. 1 (1.33), OR = 0.2152

Abbreviations: BMI, body mass index; GAD-7, General Anxiety Disorder-7; mRS, modified Ranking Scales; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation. *p<.05.

### TABLE 4  Logistic regression analysis of cognitive outcomes at 12 m in first AIS participants

| Variables                     | Events (%) | Model 1 OR     | p    | Model 2 OR     | p    | Model 3 OR     | p    |
|-------------------------------|------------|----------------|------|----------------|------|----------------|------|
| Cognitively stable/improve    |            |                |      |                |      |                |      |
| SBP < 130 mmHg                | 146 (63.32)| Reference      |      | Reference      |      | Reference      |      |
| 130 ≤ SBP < 140 mmHg          | 133 (62.15)| 0.91 (0.61–1.35)| .6330| 0.91 (0.61–1.34)| p6306| 0.87 (0.58–1.29)| p4865|
| SBP ≥ 140 mmHg                | 107 (56.02)| 0.68 (0.46–1.02)| .0628| 0.68 (0.46–1.03)| .0666| 0.66 (0.44–0.99)| .0451|

Cognitively impaired

| Variables                     | Events (%) | Model 1 OR     | p    | Model 2 OR     | p    | Model 3 OR     | p    |
|-------------------------------|------------|----------------|------|----------------|------|----------------|------|
| SBP < 130 mmHg                | 17 (7.49)  | Reference      |      | Reference      |      | Reference      |      |
| 130 ≤ SBP < 140 mmHg          | 15 (7.01)  | 0.89 (0.43–1.84)| .7496| 0.89 (0.43–1.84)| .7517| 0.95 (0.45–1.99)| .8824|
| SBP ≥ 140 mmHg                | 30 (15.71) | 2.02 (1.06–3.84)| .0322| 2.00 (1.05–3.81)| .0351| 2.17 (1.12–4.21)| .0226|

a, p<.05 in model 1; b, p<.05 in model 2; c, p<.05 in model 3.

OR1 logistic regression age, sex, and years of education.

OR2 logistic regression age, sex, years of education, and MRS.

OR3 logistic regression age, sex, years of education, recurrence of ischemic stroke.
AUTHOR CONTRIBUTIONS
X.L., J.S. and Y.W. designed the study. Y.W., S.L. and J.S. did the scientific literature search. Y.W., S.L., X.L., Y.W. collected data. Y.W., S.L., Y.P., M.W., J.S. and Y.W. analyzed data. Y.W., S.L., Y.P., J.S. and Y.W. interpreted data. Y.W. and M.W. created the tables. Y.W., S.L., Y.P., J.S. and Y.W. wrote and all authors edited the report. All authors read and approve the manuscript.

CONFLICT OF INTEREST
Authors report no conflict of interest.

ORCID
Jiong Shi MD, PhD https://orcid.org/0000-0001-7694-1366

REFERENCES
1. Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. The Lancet. 2015;385:549-562.
2. Maigeng Z, Haidong W, Jun Z, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2016;387:251-272.
3. Ali Fallata AA, Almaghrahbi TSH, Elfarrag MH, Kalanta M, Abutaaleb Qisi IM, Mirghani HO. Mild cognitive impairment among patients with diabetes in Tabuk City, the Kingdom of Saudi Arabia and its relation to glycaemic control: a case-control study. Aust Med J. 2019;12:315-320.
4. Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. J Alzheimer’s Assoc. 2018;14:263-270.
5. Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke. 2004;35:1264-1268.
6. Mijaljović MD, Pavlović A, Brainin M, et al. Post-stroke dementia - a comprehensive review. BMC Med. 2017;15:11.
7. Gregson J, Qizilbash N, Iwagami M, et al. Blood pressure and risk of dementia and its subtypes: a historical cohort study with long-term follow-up in 2.6 million people. Eur J Neurol. 2019;26:1479-1486.
8. Wang ZT, Xu W, Wang HF, et al. Blood pressure and the risk of dementia: a dose-response meta-analysis of prospective studies. Curr Neurol Neurosci Rep. 2018;18:345-358.
9. Zonneveld TP, Richard E, Vergouwen MD, et al. Blood-pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018;7:CD007858.
10. SMIfTS Group, R. Williamson J, Pajewski N, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553-561.
11. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the. Am Heart Assoc/Am Stroke Assoc Stroke. 2019;50:e344-e418.
12. Wang Y, Liao X, Wang C, et al. Impairment of cognition and sleep after acute ischaemic stroke or transient ischaemic attack in Chinese patients: design, rationale and baseline patient characteristics of a nationwide multicentre prospective registry. Stroke Vasc Neurol. 2020.
13. Unger T, Borghi C, Charach F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334-1357.
14. Quinn TJ, Elliott E, Langhorne P. Cognitive and mood assessment tools for use in stroke. Stroke. 2018;49:483-490.
15. Tan HH, Xu J, Teoh HL, et al. Decline in changing Montreal Cognitive Assessment (MoCA) scores is associated with post-stroke cognitive decline determined by a formal neuropsychological evaluation. PLOS ONE. 2017;12:e0173291.
16. Krishnan K, Rossetti H, Hynan LS, et al. Changes in montreal cognitive assessment scores over time. Assessment. 2016;24:772-777.
17. Nasi LA, Martins SCO, Gus M, et al. Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): results of a randomised controlled trial. Neurocrit Care. 2019;30:372-379.
18. Bosel J. Blood pressure control for acute severe ischemic and hemorrhagic stroke. Curr Opin Crit Care. 2017;23:81-86.
19. Petersen NH, Ortega-Gutierrez S, Wang A, et al. Decreases in blood pressure during thrombectomy are associated with larger infarct volumes and worse functional outcome. Stroke. 2019;50:1797-1804.
20. Lau KK, Li L, Simoni M, Mehta Z, Küker W, Rothwell PM. Long-term premorbid blood pressure and cerebral small vessel disease burden on imaging in transient ischemic attack and ischemic stroke. Stroke. 2018;49:2053-2060.
21. Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Prevalence of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension (Dallas, Tex: 1979). 2001;37:869-874.
22. Levine DA, Gross AL, Briceño EM, et al. Association between blood pressure and later-life cognition among black and white individuals. JAMA Neurol. 2020.77(7):810–819.
23. Ihle-Hansen H, Thommessen B, Fagerland M, Oksengard A, Wyller T, Engedal K, et al. Blood pressure control to prevent decline in cognition after stroke. Vasc Health Risk Manage. 2015;311.
24. Pearce LA, McClure LA, Anderson DC, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014;13:1177-1185.
25. Nicolas K, Levi C, Evans TJ, et al. Cognition in the first year after a minor stroke, transient ischemic attack, or mimic event and the role of vascular risk factors. Front Neurol. 2020;11:216.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.